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REGULAR ARTICLE
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Plerixafor, a direct antagonist of CXCR4/stromal-derived factor 1, can safely and rapidly

Key Points

mobilize allografts without the use of granulocyte colony-stimulating factor (G-CSF). We

• Plerixafor-based mobilization is less toxic and
more rapid relative to
G-CSF, but fewer
CD341 cells are
collected.

conducted a phase 2, multicenter, prospective study of plerixafor-mobilized HLA-identical
sibling allografts for allogeneic hematopoietic cell transplantation in recipients with
hematological malignancies. Donors (n 5 64) were treated with subcutaneous plerixafor
(240 mg/kg) and started leukapheresis (LP) 4 hours later. The primary objective was to
determine the proportion of donors who were successfully mobilized: deﬁned as collection
of $2.0 3 106 CD341 cells per kilogram recipient weight in #2 LP sessions. Recipients

• Despite lower numbers
of CD341 cells mobilized, plerixafor mobilized allografts may be
associated with similar
clinical outcomes.

subsequently received reduced intensity (RIC; n 5 33) or myeloablative (MAC; n 5 30)
conditioning. Sixty-three of 64 (98%) donors achieved the primary objective. The median
CD341 cell dose per kilogram recipient weight collected within 2 days was 4.7 (0.9-9.6).
Plerixafor was well tolerated with only grade 1 or 2 drug-related adverse events noted.
Bone pain was not observed. Plerixafor-mobilized grafts engrafted promptly. One-year
progression-free and overall survivals were 53% (95% conﬁdence interval [CI], 36% to
71%) and 63% (95% CI, 46% to 79%) for MAC and 64% (95% CI, 47% to 79%) and 70% (95% CI,
53% to 84%) for RIC recipients, respectively. Donor toxicity was reduced relative to G-CSF
mobilized related donors. This is the ﬁrst multicenter trial to demonstrate that, as an
alternative to G-CSF, plerixafor rapidly and safely mobilizes suﬃcient numbers of CD341
cells from matched sibling donors for HCT. Engraftment was prompt, and outcomes in
recipients were encouraging. This trial was registered at clinicaltrials.gov as #NCT01696461.

Introduction
The optimal source of donor hematopoietic stem cells (HSC) for hematopoietic cell transplantation
(HCT) is controversial. Granulocyte colony-stimulating factor (G-CSF)–mobilized peripheral blood
(G-PB) has replaced bone marrow (BM) as the most common allograft source in adults1 but is
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associated with donor morbidity and higher rates of chronic graftversus-host disease (GVHD) compared with BM.2,3 G-PB is the
standard graft collected from adult related donors based on past
studies showing more rapid engraftment, a shorter hospital stay,
and superior overall survival (OS) in certain studies when compared
with unmanipulated BM.3

at 1 month and 12 months as well as phone contact at 1, 6, and
12 months after LP.
Both recipients and sibling donors gave written informed consent
in accordance with the Helsinki protocol on a study approved by
the National Marrow Donor Program institutional review board and
the institutional review boards at each participating institution. The
study was monitored by the National Marrow Donor Program Data
Safety and Monitoring Board.

Although the use of G-PB has allowed a sufficient allograft to be
obtained without the need for an invasive surgical procedure,
donors can experience moderate albeit transient toxicity attributable
to G-CSF administration.4 In addition, the standard 4- to 6-day
period of G-CSF mobilization causes significant inconvenience. The
CXCR4 antagonist plerixafor mobilizes HSC into the peripheral
blood faster than G-CSF and has become a standard agent used in
combination with G-CSF for HSC mobilization prior to autologous
stem cell transplantation.5,6 Two studies from 1 center showed that
plerixafor alone given on the day of leukapheresis (LP) without
G-CSF could safely and effectively mobilize functional HSC from
healthy adult matched related donors for use in allogeneic
transplantation after myeloablative conditioning (MAC).7,8 Analyses
of allografts from these studies suggest both quantitative and
qualitative differences relative to G-PB grafts that could impact
clinical outcomes in recipients.7,8 To test the generalizability of
these single-center observations, we conducted a phase 2 multicenter trial investigating HSC mobilization with single-agent
plerixafor (without G-CSF) from matched sibling adult donors for
transplantation of patients with hematological malignancies following either MAC or reduced intensity conditioning (RIC). We
hypothesized that (1) plerixafor is a less toxic method for HSC
mobilization relative to G-CSF for donors and (2) recipient outcomes after a plerixafor mobilized HCT (P-PB) would be similar to
those observed after transplantation of G-PB.

Donors were treated with subcutaneous plerixafor at a dose of
240 mg/kg (actual weight). Four hours later, large-volume LP (at
least 4 times blood volume) was performed per standard institutional methods. The target CD341 cell dose for the donor allograft
was $4.0 3 106/kg actual recipient weight. If the target CD341 cell
dose of $4.0 3 106/kg actual recipient weight was met after the
first LP, no further collections were performed. If the LP product
collected following day 1 contained $2.0 3 106 CD341 cells per
kilogram actual recipient weight, collection was considered successful; however, the donor returned the following morning, and the
same procedures described above were repeated to attempt to
achieve the target CD341 cell dose. If the sum of the 2 collected
LP products was $2.0 3 106 CD341 cells per kilogram recipient
weight, collection was considered successful and completed. If
the sum of the 2 LP products was ,2.0 3 106 CD341 cells per
kilogram recipient weight after 2 days, collection was considered
unsuccessful, and any further plerixafor administration was at the
discretion of the treating center. However, no more than 3 total days
of plerixafor were allowed to be administered to each donor. Each
LP product was then cryopreserved before the recipient initiated
conditioning.

Patients and methods

Transplant-related procedures

Recipients and donors

MAC regimens included 1 of the following 4 combinations:
busulfan/fludarabine, busulfan/cyclophosphamide, total body irradiation (TBI)/cyclophosphamide, or TBI/etoposide. RIC regimens
included busulfan/fludarabine, melphalan/fludarabine, and fludarabine/
cyclophosphamide with dose thresholds determined by the Center
for International Blood and Marrow Transplantation Research
(CIBMTR) consensus criteria. Conditioning was not initiated until
donor allografts had been cryopreserved with cell doses confirmed.

Recipients were eligible if 18 years or older, if recipients had a
hematological malignancy suitable for HCT, if recipients had a fully
HLA-matched sibling donor, and if recipients met other institutional eligibility standards for allogeneic HCT. All recipients were
required to have adequate organ function and a Karnofsky
performance status $70. Underlying diseases included acute
myeloid leukemia, myelodysplastic syndrome, chronic myeloid
leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic
lymphocytic leukemia. Patients with acute leukemia were required
to have #5% blasts in the BM. Patients with prior allogeneic HCT
were excluded, and those with prior autologous HCT were only
allowed to undergo RIC.
At recipient registration, centers declared that an individual
recipient would receive MAC or RIC. Choice of agents for GVHD
prophylaxis was at the discretion of the treating institution provided
that (1) a calcineurin inhibitor in combination with methotrexate,
mycophenolate mofetil, or sirolimus was used; and (2) no monoclonal (eg, alemtuzumab) or polyclonal anti–T-cell antibodies (eg,
anti–thymocyte globulin) or any form of ex vivo T-cell depletion was
employed.
Donors were eligible if they were 18 to 65 years of age, HLAmatched to their siblings at HLA-A, -B, and -DRB1, satisfied institution
standard criteria to serve as a PB donor, and had adequate renal
function. Donors were followed with routine complete blood counts
876
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Donor mobilization treatment plan

Tapering of immunosuppression was not started until days 90 to
100 after HCT. Supportive care was left to institutional discretion.
G-CSF use was mandated for recipients of MAC starting at day 17
and continuing until absolute neutrophil count .1.5 3 109/L for
2 consecutive days. G-CSF use in recipients of RIC was optional.

Transplant-related procedures
Neutrophil engraftment was defined as time from day 0 of HCT to
the first of 3 consecutive measurements of absolute neutrophil
count $0.5 3 109/L. Platelet engraftment was defined as the
number of days from day 0 of HCT to the first of 3 consecutive
values of platelet count $20 3 109/L. Acute GVHD was graded
per previously published consensus criteria.9 Chronic GVHD was
graded per the National Institutes of Health (NIH) consensus
criteria.10 Nonrelapse mortality (NRM) was defined by death from
any cause in the absence of disease relapse. OS was defined as
from day 0 of HCT to death from any cause. Patients who were alive
were censored at the time last seen alive. Progression-free survival
26 MARCH 2019 x VOLUME 3, NUMBER 6
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(PFS) was defined from day 0 of HCT to relapse, disease progression, or death, whichever occurred first. GVHD-free, relapse-free
survival (GRFS) was defined according to published criteria.11

Toxicity assessment

(CI). When evaluating the incidence of acute and chronic GVHD,
death was treated as a competing risk. When computing cumulative
incidence probability of NRM and relapse, relapse and NRM,
respectively, were considered as a competing risk. Kaplan-Meier
curve was used to estimate the probability of OS, PFS, and GRFS.
Cumulative incidence and survival probabilities between the 2
groups of patients at fixed time points were compared by computing
an appropriate z-statistic based on the differences of observed
probabilities. A significance level a of 0.05 was used throughout, and
all tests are 2 sided. SAS statistical software (SAS Institute, Cary,
NC) was used to perform all statistical analyses of clinical data.

Toxicities were assessed in donors at 30, 60, 120, and 240 minutes
after administration of plerixafor on each day of collection and
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.0.3. A complete
blood count was drawn at 1 and 12 months after LP to confirm
normalization, and donors were contacted by telephone follow-up
at 1, 6, and 12 months after donation to assess for presence of
ongoing toxicities.

Results

Contemporaneous controls

Donor and recipient characteristics

A contemporaneous control group of all adult donors 18 to 65 years
of age and donating for the first time following G-CSF–only mobilization
of peripheral blood stem cells (PBSCs) enrolled in the Related Donor
Safety (RDSafe)12 study (n 5 1098) was identified for comparison of
donor toxicities and recovery at 1 month after donation.

Clinical and transplant characteristics of recipients in both MAC
(n 5 30) and RIC (n 5 33) cohorts are shown in Table 1. Donor/
recipient pairs were enrolled at 12 different centers. Patients in the
RIC arm were generally older and more likely to have a hematopoietic cell transplantation comorbidity index (HCT-CI) score $4.
Clinical characteristics of all donors are shown in Table 1. The
median age of donors was 56 (range 18-65), and the majority were
men. One donor was mobilized and leukapheresed, whose recipient
never underwent HCT due to disease relapse.

A contemporaneous control group of recipients of noncryopreserved G-PB grafts consisting of all patients from the CIBMTR
registry satisfying the following criteria: undergoing their first
allogeneic HCT, 18 years or older, HLA-matched related PBSC
recipient, from the same centers that enrolled in this study, and the
same diagnoses and conditioning regimens allowed on this study,
was selected for comparison of clinical outcomes.

Statistical considerations
This study was a phase 2 multicenter prospective trial. The primary
endpoint was the collection of sufficient CD341 cells using
plerixafor as the sole mobilizing agent. A donor was considered
successful for this endpoint if $2.0 3 106 CD341 cells per
kilogram recipient were collected in no more than 2 LP collections.
This minimum CD341 cell count was considered adequate to
promote hematopoietic engraftment based on prior studies transplanting plerixafor mobilized grafts. It was expected that collections
from 90% of donors treated with plerixafor would be successful,
and this strategy would be considered unacceptable if ,75% of
donors were successful.
Recipients were classified into 1 of 2 strata, MAC or RIC, based on
conditioning regimen planned. Recipient outcomes were analyzed
from both strata combined as well as separately for each stratum.
There was no statistical comparison of outcomes between the
strata. Recipient endpoints were all secondary endpoints and
included PFS, OS, NRM, relapse, and cumulative incidences of
acute and chronic GVHD, respectively. We also compared GRFS
as an unplanned post hoc analysis between study recipients and
CIBMTR controls due to increasing interest in this as a surrogate
endpoint for survival with good quality of life.
Descriptive statistics were used to summarize characteristics of
the study population. Categorical variables were summarized with
counts and percentages, whereas medians along with ranges were
used for continuous variables. x2 test and Wilcoxon rank sum test
were used to compare categorical variables and continuous variables, respectively, between the donors who received plerixafor
and RDSafe controls. The incidence of acute and chronic GVHD,
NRM, and relapse was quantified by computing their cumulative
incidence probability and an appropriate 95% confidence interval
26 MARCH 2019 x VOLUME 3, NUMBER 6

Toxicity in plerixafor mobilized donors
Plerixafor was generally well tolerated, with only grade 1 or 2
treatment-related adverse events noted. Bloating, diarrhea, dizziness, headache, and injection site reaction were the most
commonly observed adverse events. Across all days of collection,
the maximal grade of plerixafor-related toxicities reported were
grade 0 in 30%, grade 1 in 53%, and grade 2 in 16%. One donor
experienced a grade 3 vasovagal event at commencement of LP,
which was unrelated to plerixafor.

Mobilization efficacy and graft characteristics
The primary endpoint was achieved in 98% of donors, with only 1
donor failing to mobilize $2.0 3 106 CD341 cells per kilogram
within 2 LP sessions. The majority achieved the minimum CD341
dose in 1 LP session (70%), but only 27% achieved the 4.0 3 106
CD341 cell per kilogram target in 1 LP. After 2 LP sessions, the
median CD341 cell dose collected was 4.7 3 106/kg (Table 2).
Of donors, 72% underwent 2 LP sessions, and 5% underwent 3
(all of whom achieved the minimum successful dose after 2 LP
sessions). Quantification of specific leukocyte subsets was also
performed on plerixafor mobilized grafts. Relative to data we
previously published from G-CSF mobilized donors,13 P-PB grafts
contained greater numbers of CD31, CD41, and CD81 cells, as
noted in prior single-center studies (supplemental Table 1).7,8

Engraftment and chimerism
At 100 days after HCT, all patients in both the MAC and the RIC
cohorts had achieved neutrophil engraftment (Table 3). All patients
in the MAC arm and 97% of patients in the RIC arm had achieved
platelet engraftment. There were no cases of primary or secondary
graft failure. The median time to neutrophil engraftment was 13
and 15 days for MAC and RIC, respectively. The median time to
platelet engraftment was 19 and 18 days for MAC and RIC,
respectively. Chimerism at serial time points after HCT is displayed
in supplemental Table 2. Full donor myeloid chimerism was
PLERIXAFOR ALONE FOR DONOR STEM CELL MOBILIZATION
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Table 1. Characteristics of MAC and RIC recipients and donors
MAC

RIC

Table 1. (continued)
MAC

Donors

RIC

Number of recipients

30

33

64

Number of centers

10

11

12

Yes

22 (73)

16 (48)

51 (23-62)

62 (19-69)

56 (18-65)

No

8 (27)

17 (52)

Male

16 (53)

24 (73)

41 (64)

Female

14 (47)

9 (27)

23 (36)

6 (20)

7 (21)

24 (80)

26 (79)

Age at transplant, median (range), y
Sex, n (%)

Donors

Use of post-HCT GCSF, n (%)

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic
myelogenous leukemia; CNI, calcineurin inhibitor; MDS, myelodysplastic syndrome; MMF,
mycophenolate mofetil; MTX, methotrexate.

Donor-recipient sex match, n (%)
Female-male
Other
Karnofsky performance status, n (%)
90-100

20 (67)

15 (45)

#80

10 (33)

18 (55)

0

5 (17)

9 (27)

1

8 (27)

6 (18)

2

6 (20)

2 (6)

3

6 (20)

4 (12)

$4

5 (13)

12 (36)

HCT-CI, n (%)

Recipient CMV serostatus, n (%)
Negative

15 (50)

7 (21)

Positive

14 (47)

25 (76)

1 (3)

1 (3)

AML

12 (40)

11 (33)

ALL

8 (27)

2 (6)

CML

3 (10)

—

MDS

4 (13)

11 (33)

Lymphoma

3 (10)

9 (27)

Inconclusive or unknown
Recipient diagnosis, n (%)

Disease risk index
Low, n (%)

4 (14)

5 (17)

19 (66)

19 (63)

High, n (%)

3 (10)

6 (20)

Very high, n (%)

3 (10)

Intermediate, n (%)

Unknown, n

1

—

5 (17)

—

Cyclophosphamide/TBI

8 (27)

—

Etoposide/TBI

2 (7)

—

Melphalan/fludarabine

—

7 (21)

Busulfan/fludarabine (RIC)

—

25 (76)

Cyclophosphamide/fludarabine/TBI

—

1 (3)

GVHD prophylaxis, n (%)
CNI 1 MTX based

24 (80)

24 (70)

CNI 1 MMF based

3 (10)

5 (15)

Other
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The cumulative incidence of relapse at 1 year was 30% (95% CI,
15% to 48%) after MAC and 30% (95% CI, 16% to 47%) after RIC
(Figure 2A). NRM at 1 year was 17% (95% CI, 6% to 32%) after
MAC and 6% (95% CI, 1% to 17%) after RIC (Figure 2B). PFS at
1 year was 53% (95% CI, 36% to 71%) after MAC and 64% (95%
CI, 47% to 79%) after RIC (Figure 2C). OS at 1 year was 63%
(95% CI, 46% to 79%) after MAC and 70% (95% CI, 53% to 84%)
after RIC (Figure 2D).

Immune reconstitution was measured by CD31CD41 and CD31
CD81 T cells in the peripheral blood of patients at days 28, 100,
180, and 365 after HCT (supplemental Figure 1A-B). Notably,
median CD31CD41 cell counts were .200/mL at all times
analyzed, including day 28 in both MAC and RIC groups. Nineteen
(65%) of the MAC recipients were at risk for cytomegalovirus
(CMV) reactivation, and 3 patients (16%) experienced 1 or more
CMV reactivations in blood at a median of 43 days after transplantation (range 39-152). Twenty-seven of the 33 (82%) RIC recipients
were at risk, and 6 (22%) had at least 1 episode of CMV viremia a
median of 57 days (range 35-216) after transplantation.

15 (50)

3 (10)

Relapse, NRM, and survival

Immune reconstitution and CMV reactivation

Busulfan/fludarabine (MAC)

CNI alone

The day 1100 cumulative incidence of grades 2 to 4 and 3 to 4 acute
GVHD were 53% (95% CI, 35% to 71%) and 17% (95% CI, 6% to
32%), respectively, for patients treated with MAC and 18% (95% CI,
7% to 33%) and 3% (95% CI, 0% to 12%) for RIC-treated patients
(Figure 1A-B). The 1-year cumulative incidence of any chronic GVHD
for MAC and RIC patients was 52% (95% CI, 33% to 70%) and 39%
(95% CI, 23% to 57%), respectively (Figure 1C). The corresponding
NIH severity scores for all cGVHD patients were mild (MAC 37%; RIC
31%), moderate (MAC 44%; RIC 31%), and severe (MAC 19%; RIC
38%). We measured 1-year GRFS as an exploratory endpoint post
hoc according to previous definition.11 One-year GRFS was 23%
(95% CI, 10% to 40%) in MAC recipients and 39% (95% CI, 24% to
56%) in RIC recipients (Table 3; Figure 1D).

3

Busulfan/cyclophosphamide

—

GVHD

0

Conditioning, n (%)

CNI 1 others

achieved relatively quickly in both groups (median 100% at day 128
in both RIC and MAC), but conversion to full donor T-cell chimerism
appeared to be slower in the RIC patients.

3 (9)
—
1 (3)

Comparison with RDSafe donor and CIBMTR
recipient controls
In the RDSafe cohort, 725 (66%) donors underwent 1 day of
collection; 341 (31%) had 2 days of collection, and 32 (3%) had
3 or more days of cell collection. On the day of collection, the

26 MARCH 2019 x VOLUME 3, NUMBER 6
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Table 2. Plerixafor donor mobilization characteristics
Variable

Median (range)

Peripheral blood CD341 count (3106/mL):
day 1 preplerixafor

2.8 (0.3-28.0)

Peripheral blood CD341 count (3106/mL):
day 1, 240 min postplerixafor

19.0 (1.7-52.0)

Peripheral blood CD341 count (3106/mL):
day 1, 240 min postplerixafor: fold increase

n (%)

6.5 (0.9-26.0)

Total CD341 cell count/kg in LP product
at day 2
$2.0 3 106/kg recipient weight (yes)

63 (98)

$4.0 3 106/kg recipient weight (yes)

41 (64)

CD341 cells collected
(3106/kg recipient weight)
Day 1 (n 5 64)

2.80 (0.30-9.60)

Day 2 (n 5 48)

1.75 (0.50-4.70)

Cumulative total

4.70 (0.90-9.60)

maximum toxicity reported was significantly higher in donors receiving
G-CSF with 30% of donors experiencing grade 2 toxicities and
15% experiencing grades 3 to 4 toxicities compared with 16% of
plerixafor mobilized donors reporting grade 2 maximum toxicities
and 2% reporting grades 3 to 4 toxicities (P , .001) (Table 4). At
1 month after collection, there were no significant differences between plerixafor and G-CSF donors in terms of maximum toxicities
reported or overall recovery.
We compared clinical outcomes in recipients from this study to
a matched cohort of CIBMTR controls, stratified by conditioning
regimen intensity. There were no significant differences in hematopoietic engraftment, serial chimerism values, cumulative incidence of grades 2 to 4 and 3 to 4 acute GVHD, chronic GVHD,
1-year GRFS, NRM, PFS, or OS (Table 3) with the exception of a
significant increase in grade 2 acute GVHD in the MAC recipients
(P 5 .045). Serial immune reconstitution data were not available for
control recipients from the CIBMTR.

Discussion
The results of this study suggest that plerixafor-based donor mobilization is a less toxic and faster method to obtain hematopoietic

cells for transplantation into patients with hematological malignancies compared with G-PB, and that despite apparent differences in
allograft content, important clinical outcomes in recipients appear
similar relative to transplantation of G-PB. However, a prospective,
randomized controlled trial would be necessary to prove this.
G-CSF–based mobilization of donor peripheral blood stem cells is
usually successful, but 15% of donors experience grade 3 to 4
acute toxicity, and .50% of recipients of G-PB develop chronic
GVHD3; clearly there is room for improvement. The group at
Washington University (WashU) has pioneered the use of singleagent plerixafor and demonstrated it can rapidly mobilize cells
for transplantation.7,8 However, it is a less potent mobilizer than
G-CSF, and two-thirds of donors require 2 days of LP to collect an
adequate graft. Efforts to improve the pharmacodynamic response
to subcutaneous plerixafor, including dose escalation and IV administration, have been largely unsuccessful.8 As such, we chose to
deliver the standard Food and Drug Administration–approved dose
of 240 mg/kg administered subcutaneously to donors on this study.
Although it is indeed safe and well tolerated, only 27% of our donors
achieved the target dose in 1 LP procedure. Thus, although the
minimum CD341 cell dose was achieved after 2 days of LP in
98% of donors, future efforts to reliably reduce collection to a singleday procedure would be desirable.
Potentially important qualitative and quantitative differences comparing P-PB to G-PB could impact clinical outcomes in recipients
(supplemental Table 1). Specifically, CD341 cell doses collected
after the first day of LP are lower with P-PB, and G-PB grafts from
related donors generally contain higher numbers of CD341 cells.3
Nevertheless, data from this study and WashU suggest this does
not adversely affect the kinetics or completeness of hematopoietic
engraftment, perhaps due to improved homing efficiency or other
factors.7,8 Conversely, the content of CD31, CD41, and CD81
T cells is greater in plerixafor mobilized allografts. Although the
higher T-cell content raises concern that more acute or chronic
GVHD may occur, this has not been observed to date in the .100
patients who have received P-PB allografts at WashU. With the
exception of possibly more grade 2 acute GVHD in the MAC
recipients, we did not observe substantial increases in GVHD on
this trial. Data from WashU and another study from the HOVON
group show more plasmacytoid dendritic cell (pDC) precursors in
P-PB grafts relative to G-PB.8,14 Larger numbers of pDC in BM

Table 3. Outcomes after HCT of recipients receiving plerixafor mobilized PBSCs compared with control recipients receiving G-CSF mobilized
PBSCs from the CIBMTR
Outcome
Neutrophil engraftment by day 1100, %
Platelet engraftment by day 1100, %

MAC PLEX (n 5 30)

MAC CIBMTR (n 5 99)

P

RIC PLEX (n 5 33)

RIC CIBMTR (n 5 73)

P

100

100

—

100

100

—
.530

100

98

—

97

94

Day 100 cumulative incidence of grades 2-4 acute GVHD (range)

53 (35-71)

32 (23-42)

.045

18 (7-33)

23 (14-34)

.546

Day 100 cumulative incidence of grades 3-4 acute GVHD (range)

17 (6-32)

5 (2-10)

.110

3 (0-12)

7 (2-14)

.369

1-y cumulative incidence of chronic GVHD (range)

52 (33-70)

51 (41-60)

.913

39 (23-57)

40 (29-52)

.933

1-y cumulative incidence of disease relapse (range)

30 (15-48)

35 (26-45)

.586

30 (16-47)

47 (35-58)

.106

1-y cumulative incidence of NRM (range)

17 (6-32)

15 (9-23)

.847

6 (1-17)

7 (2-14)

.879

1-y progression-free survival (range)

53 (36-71)

49 (40-59)

.712

64 (47-79)

47 (35-58)

.095

1-y OS (range)

63 (46-79)

66 (56-75)

.816

70 (53-84)

63 (52-74)

.495

1-y GRFS (range)

23 (10-40)

30 (22-40)

.439

39 (24-56)

29 (19-40)

.289
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Figure 1. GVHD outcomes. (A) Cumulative incidence of grades II-IV acute GVHD. (B) Cumulative incidence of grades III-IV acute GVHD. (C) Cumulative incidence of
chronic GVHD. (D) One-year GRFS in RIC and MAC recipients, respectively.

grafts have been shown to be associated with improved survival and
decreased NRM after unrelated donor transplantation.13Nevertheless,
the clinical impact of these differences in graft content remains
speculative.
Immune reconstitution in our study was generally robust. Notably,
the median CD41 count after transplantation never fell below 200/mL,
even in the RIC group with a median age of 62 years. The higher
CD4 1 content of P-PB allografts relative to G-PB may have
played a role in the very low NRM observed. In addition, the
higher CD8 1 content in P-PB may be beneficial, particularly for
RIC patients. Reshef and colleagues recently described the
characteristics of G-PB donor grafts that associated with a
lower risk of disease relapse and an improvement in OS
following RIC-based HCT. 15 In an analysis of 200 patients with
hematologic malignancies who underwent HCT after RIC,
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transplantation of grafts containing a high CD81 T-cell dose
(CD8hi) resulted in improved survival due to a reduction in the risk for
relapse without a significant increase in GVHD. These CD8hi grafts
were collected almost exclusively from younger donors. The odds of
finding CD8hi donors correlated inversely with age. In that study,
elderly RIC transplant recipients were very unlikely to receive a graft
containing the ideal CD81 cell dose from their older siblings. In our
study, all of the allografts from P-PB donors were above the optimal
CD8hi level established by Reshef, despite a median age of 56,
whereas only 13% of donors over age 50 mobilized a CD8hi graft
after G-CSF in their study.15 P-PB may thus be a means to convert
an older matched sibling donor into an “optimal” donor relative to
prevention of relapse. The 39% GRFS in the RIC recipients on this
study was encouraging and suggests that testing this hypothesis in a
prospective study may have merit.
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Figure 2. Transplantation outcomes. (A) Cumulative incidence of disease relapse. (B) Cumulative incidence of NRM. (C) Progression-free survival. (D) OS in RIC and MAC
recipients, respectively.

Low rates of CMV reactivation following transplantation of P-PB
have been observed by the WashU group, hypothetically related to
the pDC precursor content.8 We observed that ,20% of the at-risk
population on this study experienced CMV reactivation, which may
be lower than historical controls but would need to be confirmed in
a controlled trial.
Although this was a prospective multicenter trial, conclusions
are limited by the single-arm design and small sample size even
with comparison with contemporaneous control groups from
the RDSafe study and CIBMTR, respectively. Although rates
of acute and chronic GVHD appeared comparable relative to
the CIBMTR control group, assessment of chronic GVHD is
fraught with error, and standard grading schemes can often
hide the actual severity of disease. In addition, formal assessment of nontraditional endpoints such as cost and quality of life
for both donors and recipients was not included, but should
26 MARCH 2019 x VOLUME 3, NUMBER 6

be components of future studies comparing methods of PB
mobilization.
In conclusion, single-agent subcutaneous plerixafor resulted in safe
and rapid CD341 cell mobilization from healthy HLA-matched
related donors. Compared with a contemporaneous control of
G-PB donors, plerixafor mobilized donors appeared to experience
significantly less grade 2 to 4 toxicities. Grafts mobilized with
plerixafor contained a several-fold increase in T and B cells relative
to traditional G-CSF mobilized grafts. Recipients of both MAC and
RIC regimens experienced rapid and durable engraftment. Within
the limits imposed by the size of our study cohort, rates of acute
and chronic GVHD, relapse, NRM, PFS, GRFS, and OS were not
demonstrably different from those in a contemporaneous control
group of recipients of G-PB from the CIBMTR. Definitive conclusions regarding recipient outcomes cannot be reached until a
randomized prospective study is performed. Therefore, until we
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Table 4. Toxicities experienced by donors on this study and CIBMTR

control group
Plerixafor

RDSafe

Number of donors

64

1098

Number of centers

12

42

0

19 (30)

188 (17)

1

34 (53)

411 (38)

2

10 (16)

328 (30)

1 (2)

164 (15)

0

33 (60)

520 (54)

1

14 (25)

308 (32)

2

8 (15)

111 (11)

0

29 (3)

,.001

Maximum toxicity at collection, n (%)

3-4

.538

Maximum toxicity at 1 mo, n (%)

3-4

P

Recovery at 1 mo, n (%)
Yes

43 (67)

590 (62)

No

21 (33)

356 (38)

0

152

Unknown

.440

have more effective mobilizing agents capable of reducing the process of collecting an allograft to a 1-day procedure for the majority
of donors, G-CSF will remain the standard. Efforts to identify such
agents are ongoing, and if successful, should be compared
prospectively to G-PB.16

Acknowledgments
This study was supported by Genzyme Corporation, a Sanofi
company, in part by National Institutes of Health (NIH), National
Cancer Institute (NCI) grant R01 1R01CA188523-01A1 (E.K.W.),
and by the Biostatistics and Bioinformatics shared resource of
Winship Cancer Institute of Emory University and NIH/NCI under
award number P30CA138292. The CIBMTR is supported primarily
by Public Health Service Grant/Cooperative Agreement
5U24CA076518 from the NCI, the National Heart, Lung, and Blood
Institute (NHLBI), and the National Institute of Allergy and Infectious
Diseases, a grant/cooperative agreement 1U24HL138660 from
NHLBI and NCI, a contract HHSH250201700006C with Health
Resources and Services Administration (Department of Health and
Human Services), 3 grants (N00014-17-1-2388, N00014-17-1-2850,
and N00014-18-1-2045) from the Office of Naval Research, and grants

from Adaptive Biotechnologies, *Amgen, Inc, anonymous donation
to the Medical College of Wisconsin, Astellas Pharma US, Atara
Biotherapeutics, Inc, Be the Match Foundation, *bluebird bio, Inc,
*Bristol Myers Squibb Oncology, *Celgene Corporation, *Chimerix, Inc,
*CytoSen Therapeutics, Inc, Fred Hutchinson Cancer Research
Center, Gamida Cell Ltd, Gilead Sciences, Inc, HistoGenetics,
Inc, Immucor, *Incyte Corporation, Janssen Scientific Affairs, LLC,
*Jazz Pharmaceuticals, Inc, Karius, Inc, Karyopharm Therapeutics,
Inc, *Kite Pharma, Inc, Medac, GmbH, *Mediware, The Medical
College of Wisconsin, *Merck & Co, Inc, *Mesoblast, MesoScale
Diagnostics, Inc, Millennium, the Takeda Oncology Co, *Miltenyi
Biotec, Inc, Mundipharma EDO, National Marrow Donor Program,
Novartis Pharmaceuticals Corporation, PCORI, *Pfizer, Inc,
*Pharmacyclics, LLC, PIRCHE AG, *Sanofi Genzyme, *Seattle
Genetics, Shire, Spectrum Pharmaceuticals, Inc, St. Baldrick’s
Foundation, Swedish Orphan Biovitrum, Inc, *Takeda Oncology,
and University of Minnesota. *Corporate members.
The content of this publication is solely the responsibility
of the authors and does not necessarily represent the official
views of the NIH. The views expressed in this article do not
reflect the official policy or position of the NIH, the Department
of the Navy, the Department of Defense, Health Resources
and Services Administration, or any other agency of the US
Government.

Authorship
Contribution: J.P.M., S.M.D., J.L.-R., M.M.H., Y.-B.C., D.M.K., M.H.,
J.F.D., M.R.L., M.E.H., A.S.A., H.F.F., H.K.D., and E.K.W. conceived
and designed the study; S.M.D., J.L.-R., M.M.H., Y.-B.C., M.H., J.F.D.,
M.R.L., M.E.H., A.S.A., H.F.F., H.K.D., E.K.W., M.C., S.H., and B.L.M.
provided study materials and/or patients; R.J.D., S.M.D., J.L.-R., H.K.,
M.P., M.M.H., Y.-B.C., D.M.K., M.H., J.F.D., M.R.L., M.E.H., B.E.S., A.S.A.,
H.F.F., H.K.D., E.K.W., M.C., S.H., and B.L.M. collected and assembled data; R.B., J.P.M., S.M.D., J.L.-R., M.M.H., Y.-B.C., D.M.K., B.E.S.,
M.H., J.F.D., M.R.L., M.E.H., A.S.A., H.F.F., H.K.D., E.K.W., M.C.,
S.H., and B.L.M. analyzed and interpreted the data; and all
authors wrote, had final approval of manuscript, and were
accountable for all aspects of the work.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Steven M. Devine, Center for International
Blood and Marrow Transplant Research (CIBMTR)–Minneapolis,
500 North 5th St, Minneapolis, MN 55401; e-mail: sdevine2@
nmdp.org.

References
1.

Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826.

2.

Anasetti C, Logan BR, Lee SJ, et al; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated
donors. N Engl J Med. 2012;367(16):1487-1496.

3.

Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of
hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(22):5074-5087.

4.

Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial
from the National Marrow Donor Program. Blood. 2009;113(15):3604-3611.

5.

DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colonystimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients
with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.

882

CHEN et al

26 MARCH 2019 x VOLUME 3, NUMBER 6

From www.bloodadvances.org by guest on April 25, 2019. For personal use only.

6.

DiPersio JF, Stadtmauer EA, Nademanee A, et al; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem
cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.

7.

Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the
CXCR4/SDF-1 interaction. Blood. 2008;112(4):990-998.

8.

Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.
Blood. 2017;129(19):2680-2692.

9.

Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.

10. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graftversus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
11. Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell
transplantation. Blood. 2015;125(8):1333-1338.
12. Switzer GE, Bruce J, Kiefer DM, et al. Health-related quality of life among older related hematopoietic stem cell donors (.60 years) is equivalent to that of
younger related donors (18 to 60 years): a related donor safety study. Biol Blood Marrow Transplant. 2017;23(1):165-171.
13. Waller EK, Logan BR, Harris WA, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naı̈ve T cells from unrelated-donor
marrow grafts: results from BMTCTN 0201. J Clin Oncol. 2014;32(22):2365-2372.
14. De Greef GE, Braakman E, Alemayehu WG, et al. Lymphocyte and hematopoietic stem and progenitor cell (HSPC) subsets mobilized by either plerixafor
or G-GCSF: a retrospective comparison of grafts harvested in healthy allogeneic stem cell donors [abstract]. Blood. 2014;124(21). Abstract 2451.
15. Reshef R, Huffman AP, Gao A, et al. High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell
transplantation with reduced-intensity conditioning. J Clin Oncol. 2015;33(21):2392-2398.
16. Hoggatt J, Singh P, Tate TA, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172(1-2):191-204.e10.

26 MARCH 2019 x VOLUME 3, NUMBER 6

PLERIXAFOR ALONE FOR DONOR STEM CELL MOBILIZATION

From www.bloodadvances.org by guest on April 25, 2019. For personal use only.

883

